An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Status:
Terminated
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal
carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
Phase:
Phase 1
Details
Lead Sponsor:
Navidea Biopharmaceuticals
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)